Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2026)

Tarsus Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $571.6 million for Q1 2026.

• In Q1 2026, Assets Average rose 30.25% year-over-year to $571.6 million; the TTM figure through Mar 2026 stood at $571.6 million (up 30.25% YoY), while the FY2025 annual figure was $469.6 million, up 46.18% from the prior year.
• Assets Average for Q1 2026 stood at $571.6 million, up from $548.4 million in the prior quarter.
• The five-year high for Assets Average was $571.6 million in Q1 2026, with the low at $180.2 million in Q1 2022.
• The 5-year median for Assets Average is $307.4 million (2024), against an average of $340.3 million.
• The sharpest annual moves came in 2023 and 2024: Assets Average retreated 7.87% in 2023, then jumped 81.47% in 2024.
• Tarsus Pharmaceuticals' Assets Average stood at $232.2 million in 2022, then grew by 14.97% to $266.9 million in 2023, then jumped by 41.11% to $376.6 million in 2024, then jumped by 45.59% to $548.4 million in 2025, then gained by 4.25% to $571.6 million in 2026.
• Business Quant data shows TARS's Assets Average at $571.6 million in Q1 2026, $548.4 million in Q4 2025, and $514.8 million in Q3 2025.